A woman sits in the clinic with her ultrasound report folded in her hand. Halfway down the page is a line she has read many times: "Bulky uterus with heterogeneous myometrium, features suggestive of adenomyosis." She has been trying to conceive for three years. IVF has already been suggested. Her question is simple: does this change anything?
The short answer is that adenomyosis can lower the chance of IVF working, but it does not close the door. The longer answer involves some uncertainty, and patients deserve to hear where the evidence is firm and where it is still thin.
What the report is describing
The uterus has two main layers. The inner lining, called the endometrium, is where an embryo implants and the tissue that sheds each month as a period. Around it lies a thick wall of muscle, called the myometrium. In adenomyosis, islands of lining-type tissue are found inside that muscle wall.
These islands respond to hormones each month. The surrounding muscle thickens and can become inflamed, so the uterus may enlarge. Doctors describe two broad patterns:
- Diffuse adenomyosis: spread through large parts of the wall, often more on one side (front or back) than the other.
- Focal adenomyosis or adenomyoma: a more defined lump within the wall, which can look a little like a fibroid on a scan.
Common symptoms are heavy periods, painful periods and a dragging pelvic pain. Many women have none of these. In India, heavy bleeding over years often leaves women anaemic, and tiredness may be blamed on work or housework when low haemoglobin is the real cause.
How it is diagnosed
A transvaginal ultrasound (a scan done with a thin probe placed in the vagina) is usually the first test. An international group of ultrasound experts, the MUSA group, has agreed common terms for the features doctors look for: an asymmetrically thick wall, small cysts in the muscle, fan-shaped shadowing and an unclear border between lining and muscle. Using shared terms helps reports from different centres mean the same thing.
MRI is sometimes added when the scan is unclear, when surgery is being considered, or when fibroids and adenomyosis need to be told apart. Ultrasound findings depend heavily on the experience of the person doing the scan, so a second opinion scan is reasonable if the report surprises you.
Adenomyosis and endometriosis (lining-type tissue outside the uterus) often occur together. If you have one, your doctor may look for signs of the other.
What the research says about IVF outcomes
The most quoted analysis is a 2014 systematic review and meta-analysis in Human Reproduction by Vercellini and colleagues. It pooled 9 studies including 1,865 women having IVF or ICSI (ICSI is a technique where a single sperm is injected into each egg). Clinical pregnancy, meaning a pregnancy seen on ultrasound, occurred in 40.5% of women with adenomyosis and 49.8% of women without it. Overall, the chance of clinical pregnancy was about 28% lower with adenomyosis. Miscarriage was also more frequent: about 32% of pregnancies in women with adenomyosis compared with about 14% in those without.
These figures need careful reading. The studies were observational, they differed a lot from each other, and they measured pregnancy rather than live birth. Mild disease and severe disease were often grouped together. So the figures show a real association, but they cannot tell an individual woman what her own chance will be.
Researchers think adenomyosis may affect implantation in several ways: abnormal contractions of the uterine muscle, inflammation near the lining, and changes in how receptive the lining is to an embryo. None of these is fully proven.
The suppression question: does pretreatment help?
For many years, a common plan has been to freeze all embryos after egg collection, then give injections of a GnRH agonist for two or three months before transferring an embryo. A GnRH agonist is a medicine that switches off the ovaries temporarily and creates a short, reversible menopause-like state. The idea is that lower oestrogen shrinks the adenomyosis and calms inflammation, so the uterus is more ready when the embryo goes in.
It is a logical idea. The question is whether it actually leads to more babies.
A systematic review and meta-analysis published in Reproductive BioMedicine Online in 2025 (Steinmann and colleagues) looked at exactly this. It found seven retrospective studies (studies looking back at past records) and only one randomised trial. When women given GnRH agonist pretreatment before a hormone-prepared frozen transfer were compared with women given hormone preparation alone, live birth rates were similar (odds ratio 1.19, 95% confidence interval 0.69 to 2.06). Clinical pregnancy and miscarriage rates were also similar. The authors concluded that current evidence does not show pretreatment is better, and that randomised trials are needed.
In plain words: GnRH agonist pretreatment before a frozen embryo transfer has not been shown to improve the chance of a live birth in women with adenomyosis. The wide confidence interval means a modest benefit has not been ruled out either, especially for particular groups such as women with severe or diffuse disease. The honest position is "unproven", which is different from "harmful" and different from "proven".
This matters because pretreatment has costs. It adds two or three months before transfer, which is a real concern for women in their late thirties. It can cause hot flushes, headaches, low mood and vaginal dryness. It adds to an out-of-pocket bill that most Indian couples pay without insurance. Some doctors still offer it, particularly for large or symptomatic disease, and that can be a reasonable shared decision. What you should expect is a frank conversation about the uncertainty.
Other parts of a typical plan
- Full fertility assessment: egg reserve (AMH blood test and antral follicle count on scan), semen analysis and tube assessment. Age and egg reserve often matter more to the final outcome than the adenomyosis itself.
- Frozen transfer: many specialists prefer to freeze embryos and transfer later in a hormone-prepared cycle, so the uterus is not exposed to the very high hormone levels of stimulation.
- One embryo at a time: the ESHRE guideline on the number of embryos to transfer (2024) supports single embryo transfer to reduce twin pregnancy. Twins carry higher risks, and a uterus with adenomyosis is already at higher risk of complications.
- Surgery only for selected cases: removing a focal adenomyoma is occasionally discussed. Evidence that it improves fertility is limited, and it can weaken the uterine wall, which may matter in a later pregnancy. It is not routine.
- Treat anaemia first: correcting iron deficiency before treatment helps general health and pregnancy.
Be wary of costly extras offered with promises of better implantation. Ask what evidence supports each one.
After a positive test
Pregnancies in women with adenomyosis are watched a little more closely. Report bleeding or pain early, keep regular antenatal visits and continue iron if prescribed.
Questions to ask your doctor
- How extensive is my adenomyosis, and is it diffuse or focal?
- Do I also have signs of endometriosis?
- How do my age and egg reserve affect my chances, compared with the adenomyosis?
- What are the benefits, risks and delay of GnRH agonist pretreatment in my case, given the evidence is uncertain?
- Will you transfer one embryo at a time?
- Is surgery being suggested, and what are the risks for a future pregnancy?
This article is general information and does not replace individual advice from your doctor.
References
- Vercellini P, Consonni D, Dridi D, et al. Uterine adenomyosis and in vitro fertilization outcome: a systematic review and meta-analysis. Human Reproduction, 2014. https://doi.org/10.1093/humrep/deu041
- Steinmann M, Anthon C, Kohl Schwartz AS, et al. GnRH agonist pretreatment prior to frozen embryo transfer in women with adenomyosis: a systematic review and meta-analysis. Reproductive BioMedicine Online, 2025. https://doi.org/10.1016/j.rbmo.2025.105075
- Van den Bosch T, et al. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group. Ultrasound in Obstetrics & Gynecology, 2015. https://doi.org/10.1002/uog.14806
- ESHRE Guideline Group on the Number of Embryos to Transfer. ESHRE guideline: number of embryos to transfer during IVF/ICSI. Human Reproduction, 2024. https://doi.org/10.1093/humrep/deae010
- National Health Service (NHS). Adenomyosis. https://www.nhs.uk/conditions/adenomyosis/
